Please assess the completion status of the following clinical trial:

Trial Title: Zevalin Twice in Aggressive Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-75~2. Diagnosis of CD20+ B-diffuse large cell de novo or transformed or follicular lymphoma grade IIIb~3. Stage II, III, IV according to Ann Arbor criteria~4. Chemoresistant disease after first line treatment (CHOP-like + Rituximab) or relapsed patients after one or two lines of chemotherapy not-eligible for high dose chemotherapy and autologous stem cell transplantation~5. Performance status 0-2 according to WHO criteria~6. HIV negativity~7. Normal liver, lung and kidney function: conjugated bilirubin up to 2 x ULN, alkaline phosphatase and transaminases up to 2 x ULN, creatinine clearances ≥45 ml/min~8. Neutrophils count ³ 1.5 x 109/l, Haemoglobin ³ 9 g/dl, Platelets ³ 150 x 109/l and bone marrow involvement \< 25% before first Zevalin infusion.~9. Neutrophils count ³ 1.5 x 109/l, Haemoglobin ³ 9 g/dl, Platelets ³ 100 x 109/l before second Zevalin infusion~10. Use of effective contraception for the entire treatment period in patients sexually active~11. Negative pregnancy test in child bearing potential women~12. Life expectancy \> 6 months~13. Written informed consent~Exclusion Criteria:~1. More than two lines of prior chemotherapy before study entry~2. Prior high dose chemotherapy and autologous stem cell transplantation~3. HIV positivity~4. HBV positivity with the exception of patients with HBVcAb +, HbsAg -, HBs Ab+/- with HBV-DNA negative~5. HCV positivity with the exception of patients with no signs of active chronic hepatitis histologically confirmed~6. History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances~7. Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug~8. Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure (Attachment 5, NYHA Classification of Cardiac Disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis~9. Pregnant or breastfeeding~10. CNS lymphoma involvement.~11. History of malignant carcinoma within the last 3 years other than squamous cell and basal cell carcinoma.~12. Cardiac failure with VEF \< 40%~13. Clinical evidence of not controlled infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 90Y-Ibritumomab Tiuxetan double dose (Type: EXPERIMENTAL): 90Y-Ibritumomab Tiuxetan administered at 0.4 mCi/kg at phase 2 and then at 0.2 mCi/kg at phase 3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues